Cargando…

The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer

BACKGROUND: We aimed to evaluate the prognostic value of the lymph node ratio (LNR) in patients with axillary lymph node-positive triple-negative breast cancer (TNBC). METHODS: The prognostic efficacy was investigated in the first cohort from the Surveillance, Epidemiology, and End Results (SEER) da...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Min, Zhang, Jia-Xin, Jiang, Yi-Zhou, Chen, Ying-Le, Yang, Hai-Yuan, Tang, Li-Chen, Shao, Zhi-Ming, Di, Gen-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546527/
https://www.ncbi.nlm.nih.gov/pubmed/28496004
http://dx.doi.org/10.18632/oncotarget.17413
_version_ 1783255568055533568
author He, Min
Zhang, Jia-Xin
Jiang, Yi-Zhou
Chen, Ying-Le
Yang, Hai-Yuan
Tang, Li-Chen
Shao, Zhi-Ming
Di, Gen-Hong
author_facet He, Min
Zhang, Jia-Xin
Jiang, Yi-Zhou
Chen, Ying-Le
Yang, Hai-Yuan
Tang, Li-Chen
Shao, Zhi-Ming
Di, Gen-Hong
author_sort He, Min
collection PubMed
description BACKGROUND: We aimed to evaluate the prognostic value of the lymph node ratio (LNR) in patients with axillary lymph node-positive triple-negative breast cancer (TNBC). METHODS: The prognostic efficacy was investigated in the first cohort from the Surveillance, Epidemiology, and End Results (SEER) dataset (n=4114) and was further validated in an independent cohort from Fudan University Shanghai Cancer Center (n=417). Patients were classified into low-, medium- and high-risk LNR groups. RESULTS: Multivariate analysis revealed that the LNR was an independent predictor of overall survival (hazard ratio (HR) for high-risk LNR: 3.24; 95% confidence interval (CI): 2.56 to 4.09) and breast cancer-specific survival (HR for high-risk LNR: 3.57; 95% CI: 2.76 to 4.62) in the SEER population and also for disease-free survival (HR for high-risk LNR: 4.29; 95% CI: 2.24-8.21) in the validation population. Subgroup analysis revealed that patient classification according to the LNR could discriminate among groups of patients with different survival rates based on pathological nodal (pN) staging. CONCLUSION: The LNR shows potential for use as an additional prognostic factor for TNBC patients with positive lymph node involvement. Considering the heterogeneity of TNBC, use of the LNR might allow for optimization of the pN staging system and should be considered when making treatment decisions.
format Online
Article
Text
id pubmed-5546527
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55465272017-08-23 The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer He, Min Zhang, Jia-Xin Jiang, Yi-Zhou Chen, Ying-Le Yang, Hai-Yuan Tang, Li-Chen Shao, Zhi-Ming Di, Gen-Hong Oncotarget Clinical Research Paper BACKGROUND: We aimed to evaluate the prognostic value of the lymph node ratio (LNR) in patients with axillary lymph node-positive triple-negative breast cancer (TNBC). METHODS: The prognostic efficacy was investigated in the first cohort from the Surveillance, Epidemiology, and End Results (SEER) dataset (n=4114) and was further validated in an independent cohort from Fudan University Shanghai Cancer Center (n=417). Patients were classified into low-, medium- and high-risk LNR groups. RESULTS: Multivariate analysis revealed that the LNR was an independent predictor of overall survival (hazard ratio (HR) for high-risk LNR: 3.24; 95% confidence interval (CI): 2.56 to 4.09) and breast cancer-specific survival (HR for high-risk LNR: 3.57; 95% CI: 2.76 to 4.62) in the SEER population and also for disease-free survival (HR for high-risk LNR: 4.29; 95% CI: 2.24-8.21) in the validation population. Subgroup analysis revealed that patient classification according to the LNR could discriminate among groups of patients with different survival rates based on pathological nodal (pN) staging. CONCLUSION: The LNR shows potential for use as an additional prognostic factor for TNBC patients with positive lymph node involvement. Considering the heterogeneity of TNBC, use of the LNR might allow for optimization of the pN staging system and should be considered when making treatment decisions. Impact Journals LLC 2017-04-25 /pmc/articles/PMC5546527/ /pubmed/28496004 http://dx.doi.org/10.18632/oncotarget.17413 Text en Copyright: © 2017 He et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Clinical Research Paper
He, Min
Zhang, Jia-Xin
Jiang, Yi-Zhou
Chen, Ying-Le
Yang, Hai-Yuan
Tang, Li-Chen
Shao, Zhi-Ming
Di, Gen-Hong
The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer
title The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer
title_full The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer
title_fullStr The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer
title_full_unstemmed The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer
title_short The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer
title_sort lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546527/
https://www.ncbi.nlm.nih.gov/pubmed/28496004
http://dx.doi.org/10.18632/oncotarget.17413
work_keys_str_mv AT hemin thelymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer
AT zhangjiaxin thelymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer
AT jiangyizhou thelymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer
AT chenyingle thelymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer
AT yanghaiyuan thelymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer
AT tanglichen thelymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer
AT shaozhiming thelymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer
AT digenhong thelymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer
AT hemin lymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer
AT zhangjiaxin lymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer
AT jiangyizhou lymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer
AT chenyingle lymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer
AT yanghaiyuan lymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer
AT tanglichen lymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer
AT shaozhiming lymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer
AT digenhong lymphnoderatioasanindependentprognosticfactorfornodepositivetriplenegativebreastcancer